在原发性内分泌抵抗性乳腺癌中对TLR2的分析
Yunmei Wang1,2, Guangxi Wang2, Xiang Wang2
1Department of Medical Oncology, First Affiliated Hospital of Xi'an Jiao Tong University, 710061 Xi'an, Shaanxi, China.
Frontiers in bioscience (Landmark edition)
|February 29, 2024
概括
收费类受体2 (TLR2) 与三重阳性乳腺癌中他莫西芬耐药性有关. 降低TLR2的调节恢复了灵敏度,这表明它可能预测内分泌抵抗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 之前的研究表明,Toll样受体2 (TLR2) 预测了HER2阳性乳腺癌中的内分泌耐药性.
- 在三重阳性乳腺癌 (TPBC) 中,TLR2对内分泌疗法耐药性的作用尚不清楚.
研究的目的:
- 调查TPBC中TLR2与他莫西芬 (TAM) 耐药性之间的关联.
- 探索TLR2作为内分泌耐药性的潜在预测标志物.
主要方法:
- 对TLR2表达的生物信息分析.
- 在TPBC组织和细胞系上进行质谱,RT-PCR和西部斑.
- 建立和分析抗TAM细胞系 (BT474-TAM) 和TLR2下调试验.
主要成果:
- 在乳腺癌患者中,TLR2表达与无复发生存率降低相关.
- 在抗TAM的TPBC组织和细胞系中,TLR2蛋白水平显著更高.
- 在BT474-TAM细胞中TLR2的下调恢复了对TAM的敏感性.
结论:
- 在TPBC中,TLR2与他莫西芬耐药性有关.
- TLR2可以作为TPBC中原发性内分泌耐药性的预测标志物.
- 向TLR2可能为克服内分泌抵抗提供治疗潜力.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


